”BIOHAVEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS”
★Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
★Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of oral zavegepant, prompting $100 million Royalty Pharma milestone payment
今日はBiohavenの2021年1Q発表
CGRP拮抗薬関係は非常に順調な様子。
★昨年3月発売のrimegepantは1年で118億14百万円（1億740万ドル）。
★次なるzavegepantは第2相/第３相スタートで約2900名が登録されて、1億ドルがマイル支払いされたとの事。
※我らBHV-3100は今年暮れにphase１をスタートする計画なんだが・・・
大いに期待できるなw マイルはお幾ら？(^^♪ｼﾒｼﾒ
”BIOHAVEN REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS”
★Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020
★Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of oral zavegepant, prompting $100 million Royalty Pharma milestone payment